Actavis buying Warner Chilcott in all-stock transaction valued at about $8.5 billion

NEW YORK, N.Y. – Actavis is buying Warner Chilcott in an all-stock transaction valued at about $8.5 billion which would create the third-biggest specialty pharmaceutical company in the U.S.

The new company is expected to be called Actavis PLC and will be incorporated in Ireland, where Warner Chilcott is currently incorporated.

Warner Chilcott shareholders would own a 23 per cent stake in the new company.

Warner Chilcott PLC shareholders will receive 0.160 shares of the new company for each share they own. This equals $20.08 per share, which is a 5 per cent premium to Friday’s closing price of $19.21. Actavis Inc. shareholders will receive one share of the new company for each share they own at closing.

Both companies’ boards unanimously approved the deal, which is expected to close by year’s end.

Warner Chilcott’s stock rose slightly in Monday premarket trading.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.